Mayo Clinic News Network

News Resources

Paul Scotti (@pscotti)

Activity by Paul Scotti

Paul Scotti (@pscotti) posted · Mon, Dec 8 11:39am · View  

Immune Function Marker Does Not Predict Benefit of Trastuzumab in HER-2+ Breast Cancer Patients, Study Finds

JACKSONVILLE, Fla. — A marker of immune function that predicts for better outcomes in patients treated with chemotherapy for triple negative breast cancer is also linked to improved prognosis in patients treated with chemotherapy for HER2-positive breast cancer. But that marker — the quantity of tumor-infiltrating lymphocytes (S-TILs) in a biopsy — appears irrelevant when trastuzumab is used.

[...]

Click here to view the rest of the post

Login here to comment.

Paul Scotti (@pscotti) posted · Sun, Nov 9 9:00am · View  

Combination Therapy Offers Quicker, Less Toxic Eradication of Hepatitis C in Patients with Transplanted Livers

JACKSONVILLE, Fla., Nov. 9, 2014 — All patients with hepatitis C who receive a liver transplant will eventually infect their new livers. These transplanted organs then require anti-viral treatment before they become severely damaged. But traditional post-transplant hepatitis C therapy can take up to a year, is potentially toxic and can lead to organ rejection.

Now, at the American Association for the Study of Liver Diseases (The Liver Meeting® 2014) in Boston, researchers at Mayo Clinic report that use of two new oral medications post-transplant is safe and beneficial, and requires only 12 weeks of treatment.

“This is the first study to examine the use of these two new drugs — simeprevir and sofosbuvir — in liver transplant recipients, and, based on this large study, we find it to be a better option than current treatment,” says the study’s lead researcher, Surakit Pungpapong, M.D., a transplant hepatologist and an associate professor of medicine at Mayo Clinic in Florida.

Journalists: Soundbites with Dr. Pungpapong are available in the downloads.

MEDIA CONTACT: Paul Scotti, Mayo Clinic Public Affairs, 904-953-0199. Email: scotti.paul@mayo.edu [...]

Click here to view the rest of the post

Login here to comment.

Paul Scotti (@pscotti) posted · Mon, Oct 20 6:00pm · View  

Trastuzumab (Herceptin) Continues to Show Life-Altering Benefit

large crowd of women in pink t shirts for breast cancer awareness


Years After Treatment for HER2-Positive Early Stage Breast Cancer Trastuzumab Shows Life-Altering Benefit 

JACKSONVILLE, Fla. — After following breast cancer patients for an average of eight-plus years, researchers say that adding trastuzumab (Herceptin) to chemotherapy significantly improved the overall and disease-free survival of women with early stage HER2-positive breast cancer.

They found that the use of trastuzumab produced a 37 percent improvement in survival and a 40 percent reduction in risk of cancer occurrence, compared to patients treated with chemotherapy alone.

These findings, published in the Journal of Clinical Oncology, demonstrate how important trastuzumab has been to the treatment of this form of breast cancer, says the study’s lead author, Edith A. Perez, M.D., deputy director at large, Mayo Clinic Cancer Center and director of the Breast Cancer Translational Genomics Program at Mayo Clinic in Florida. [...]

Click here to view the rest of the post

Login here to comment.

Paul Scotti (@pscotti) posted · Tue, Sep 30 3:27pm · View  

Dados de estudos clínicos mundiais de dois medicamentos para câncer de mama HER2-positivo mostra que o trastuzumabe deve permanecer como o padrão de tratamento

JACKSONVILLE, Flórida 30 de setembro de 2014 — Análises em mais de 8 mil mulheres, que participaram do maior estudo mundial de dois medicamentos para o câncer de mama HER2-positivo, reforçam outras descobertas de estudos clínicos mostrando que o trastuzumabe (Herceptin) deve permanecer como o padrão de tratamento desse tipo de câncer, diz uma pesquisadora da Clínica Mayo. [...]

Click here to view the rest of the post

Login here to comment.

Paul Scotti (@pscotti) posted · Tue, Sep 30 2:41pm · View  

Datos de un ensayo clínico realizado a nivel mundial con dos fármacos contra el cáncer de mama HER2-positivo muestran que el trastuzumab debería permanecer como tratamiento estándar

JACKSONVILLE, Florida, 30 de septiembre 2014 — Investigaciones en más de 8.000 mujeres, que participaron en el estudio más grande del mundo de dos tratamientos para el cáncer de mama HER2-positivo, refuerzan otros hallazgos de este ensayo clínico que demuestran que el fármaco trastuzumab (Herceptin) debiera seguir siendo el tratamiento estándar en este tipo de cáncer, expresa una investigadora de la Clínica Mayo. [...]

Click here to view the rest of the post

Login here to comment.

Paul Scotti (@pscotti) posted · Mon, Sep 29 10:00am · View  

Data From Worldwide Trial of Two HER2-Positive Breast Cancer Drugs Shows That Trastuzumab Should Remain as Standard of Care

JACKSONVILLE, Fla., Sept. 29, 2014 — Analysis of more than 8,000 women who participated in the world’s largest study of two treatments for HER2-positive breast cancer reinforces other findings from the clinical trial showing that trastuzumab (Herceptin) should remain the standard of care for this cancer, says a Mayo Clinic researcher.

[...]

Click here to view the rest of the post

Login here to comment.

Paul Scotti (@pscotti) posted · Fri, Sep 12 1:22pm · View  

Physicians Find Liver Transplant Patients Can Avoid Costly Stay In ICU Post Surgery

JACKSONVILLE, Fla., Sept. 12, 2014 — The liver transplant team at Mayo Clinic in Florida has found, based on 12 years of experience, that more than half of patients receiving a new liver can be “fast-tracked” to return to a surgical ward room following their transplant, bypassing a one- or two-day stay in the Intensive Care Unit (ICU).

In the September issue of the American Journal of Transplantation, the physicians and researchers have turned their knowledge of who can be safely fast-tracked into a scoring system that other transplant centers can also use — thus sparing patients potentially overly aggressive treatment and saving substantial health care dollars.

MEDIA CONTACT: Paul Scotti, Mayo Clinic Public Affairs, 904-953-0199. Email: scotti.paul@mayo.edu

[...]

Click here to view the rest of the post

Login here to comment.

Paul Scotti (@pscotti) posted · Tue, Sep 2 9:00am · View  

Mayo Clinic, University of North Florida Host Tenth Annual Upbeat Pink: A Musical Tribute to Breast Cancer Survivorship

JACKSONVILLE, Fla., Sept. 2, 2014 – Mayo Clinic and the University of North Florida are honoring Upbeat Pink ConcertNational Breast Cancer Awareness Month in October by hosting the tenth annual “Upbeat Pink: A Musical Tribute to Breast Cancer Survivorship” concert on Friday, Oct. 10 at 7:30 p.m. in Lazzara Performance Hall, UNF Fine Arts Building on the university’s campus in Jacksonville. The Upbeat Pink concert is free and open to the public.

The theme for this year’s program, “Dancing with the Survivors,” showcases a variety of dance music performed by the UNF Wind Symphony, conducted by Gordon Brock, D.M.A., and features special guest artist and multi-instrumentalist,  Bill Prince, D.M.A.

Guest speakers will include Laura Vallow, M.D., radiation oncologist at Mayo Clinic and Dianne Wagner, a local breast cancer survivor.
[...]

Click here to view the rest of the post

Login here to comment.

Load More    

Loading information...